# Nextech Invest

> Nextech Invest is a VC fund in Zürich backing Biotechnology and Health Care. See 103 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Zürich, Switzerland
- Total investments: 103
- Last investment: Jun 2026
- Lead investor: 33%
- Fund size: $64M
- Last fund: Jul 2016
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/nextech-invest-ltd.
- X (Twitter): https://twitter.com/nextechinvest
- Website: http://www.nextechinvest.com

Nextech Invest is a venture capital and private equity firm specializing in early, mid stage and late stage, and emerging growth investments. The firm also invests in incorporation, spin-outs, reverse-take-over, and PIPE transactions. It only considers investments where evidence in preclinical animal models that a drug is efficacious is availableor a device prototype fulfills the requirements. The firm seeks to invest in the field of information technology, biotechnology, healthcare with a focus on oncology companies developing cancer drugs and diagnostics. It prefers to invest in life science and enabling technologies with a focus on interdisciplinary technical and scientific projects, therapies, diagnostics, medical technologies, and services. The firm seeks to invest in companies based in Africa, Middle East, Asia, North America, Europe including Switzerland, Germany, and neighboring regions. It also considers co-investments in rest of Europe. The firm seeks to invest between CHF 1 million ($0.93 million) and CHF 5 million ($4.7 million) per financing round. It seeks a Board position in the portfolio companies. The firm seeks to exit its investments within three years via trade sale. Nextech Invest Ltd. was founded in 1998 and is based in Zurich, Switzerland.

## Contacts

5 contacts available for Nextech Invest. Shizune tracks 7 team members at Nextech Invest. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/nextech-invest?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 60 | 58% |
| Health Care | 39 | 38% |
| Therapeutics | 26 | 25% |
| Medical | 22 | 21% |
| Pharmaceutical | 20 | 19% |

21 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 36 | 35% |
| Series C | 19 | 18% |
| Series A | 17 | 17% |
| Post-IPO Equity | 8 | 8% |
| Series D | 4 | 4% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 55 | 53% |
| Germany | 3 | 3% |
| United Kingdom | 2 | 2% |
| China | 1 | 1% |
| Canada | 1 | 1% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Alfred Scheidegger | CEO | 1 | https://shizune.co/investors/profile/alfred-scheidegger |
| Kanishka Pothula | Partner | 12 | https://shizune.co/investors/profile/kanishka-pothula |
| Megan Graziano | Director Of Operations | 0 | https://shizune.co/investors/profile/megan-graziano |
| Melissa McCracken | Partner | 8 | https://shizune.co/investors/profile/melissa-mccracken |
| Thilo Schroeder | Managing Partner | 20 | https://shizune.co/investors/profile/thilo-schroeder |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Flare Therapeutics | Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation. | $85M | Series C | Jun 30, 2026 |  |
| Stipple Bio | Stipple Bio is a biotech company that focuses on advancing cellular profiling and target discovery using epitope-level resolution technologies. It develops proprietary platforms that analyze cellular interactions, enabling researchers to identify precise therapeutic targets for drug development. The company’s approach is particularly applied inoncology, where it aims to discover tumor-specific cell surface epitopes to create safer and more effective treatments. Its “Pointillist” platform is designed to map these epitopes with high precision, helping overcome limitations of traditional therapies such as off-target toxicity. | $100M | Series A | Apr 06, 2026 |  |
| Atavistik Bio | Atavistik Bio is a biotechnology company that specializes in the discovery and development of precision allosteric small molecules aimed at treating metabolic diseases and cancer. The company aims to revolutionize therapeutic approaches by focusing on selective allosteric therapeutics, which can potentially transform treatment options for seriousdiseases. | $40M | Series B | Mar 05, 2026 |  |
| Parabilis Medicines | Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach. | $305M | Series F | Jan 08, 2026 |  |
| Atavistik Bio | Atavistik Bio is a biotechnology company that specializes in the discovery and development of precision allosteric small molecules aimed at treating metabolic diseases and cancer. The company aims to revolutionize therapeutic approaches by focusing on selective allosteric therapeutics, which can potentially transform treatment options for seriousdiseases. | $120M | Series B | Dec 18, 2025 |  |
| Tango Therapeutics | Tango Therapeutics operator of a biotechnology company created to discover novel drug targets and deliver the next generation of targeted therapies to people with cancer. The company's research leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at driver genes in cancer that are focused onthree core areas, including counteracting tumor suppressor gene loss, reversing the ability of cancer cells to evade the immune system and identifying novel combinations, enabling patients to get therapies that are more effective than single-agent therapy. | $197M | Post-IPO Equity | Oct 23, 2025 |  |
| Electra Therapeutics | Electra Therapeutics is a clinical stage biotechnology company developing therapies for cancer and other immunological diseases. | $183M | Series C | Oct 22, 2025 |  |
| Tubulis | Tubulis is a biotechnology company that develops antibody-drug conjugates (ADCs) for targeted cancer therapy. The company combines proprietary technologies with disease-specific biological insights to create highly stable and effective protein-drug conjugates. Its platform enables the design of ADCs with improved delivery, reduced toxicity, andenhanced therapeutic potential across various cancer types, including solid and hematologic tumors. Tubulis is advancing a pipeline of experimental drug candidates, such as TUB-040 and TUB-030, which are currently being evaluated in clinical settings for cancers like ovarian and lung cancer. The company also collaborates with industry partners and leverages its proprietary conjugation technologies to expand the scope and effectiveness of targeted oncology treatments. | $400.6M | Series C | Oct 15, 2025 |  |
| ORIC Pharmaceuticals | ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate,ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeuticsacross a variety of solid tumors. ORIC’s second product candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens. Beyond these two product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC’s scientific founders, Charles Sawyers, MD, and Scott Lowe, PhD, have long records of discovering novel targets in cancer that have led to innovative treatments. | $125M | Post-IPO Equity | May 28, 2025 |  |
| AIRNA | AIRNA is a biotech company that is pioneering RNA editing therapies to improve the health of individuals suffering from both rare and common ailments. | $155M | Series B | Apr 01, 2025 |  |

10 of 103 investments shown.

## Co-investors
- [The Column Group](https://shizune.co/investors/profile/the-column-group) — VC Fund, 30 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 27 deals together
- [Boxer Capital](https://shizune.co/investors/profile/boxer-capital) — VC Fund, 25 deals together
- [Casdin Capital](https://shizune.co/investors/profile/casdin-capital) — VC Fund, 22 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 20 deals together
- [Logos Capital](https://shizune.co/investors/profile/logos-capital) — VC Fund, 16 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Nextech Invest invest in?

Nextech Invest invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series C stage. Most of the 103 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Nextech Invest?

Public channels for Nextech Invest include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Nextech Invest?

The team at Nextech Invest includes Alfred Scheidegger (CEO), Kanishka Pothula (Partner) and Megan Graziano (Director Of Operations), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co